CymaBay Therapeutics

$4.65
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.07 (+1.53%) As of 6:20 PM UTC today

Why Robinhood?

You can buy or sell CBAY and other stocks, options, and ETFs commission-free!

About CBAY

CymaBay Therapeutics Inc. Common Stock, also called CymaBay Therapeutics, is a clinical stage biopharmaceutical company, focused on developing and providing access to therapies for patients with liver and other chronic diseases with high unmet medical need. Its products include MBX-8025 and Arhalofenate, MBX-8025 aims to treat lipid and liver diseases while Arhalofenate intends to reduce gout flares and serum uric acid. The company was founded on October 5, 1988 and is headquartered in Newark, CA. The listed name for CBAY is CymaBay Therapeutics Inc. Common Stock.

CEO
Sujal Shah
Employees
60
Headquarters
Newark, California
Founded
1988
Market Cap
350.45M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
1.61M
High Today
$4.71
Low Today
$4.54
Open Price
$4.59
Volume
806.41K
52 Week High
$9.06
52 Week Low
$1.21

CBAY Earnings

-$0.43
-$0.29
-$0.14
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 19, After Hours

You May Also Like

OFG
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure